What Is a Medical Revolving Line of Credit?
Why Institutional Capital Makes the Difference
A medical revolving line of credit is a reusable credit facility issued to a patient for healthcare services, allowing them to pay current and future balances at their health system up to an approved limit without reapplying for each episode of care.
Unlike single-use medical loans or in-house payment plans, a revolving line of credit functions like a dedicated healthcare credit account. As the patient makes payments, available credit is restored and can be used again.
One application. One account. Ongoing access to financing across multiple episodes of care at the same health system.
Why the Revolving Structure Matters
For patients managing ongoing or chronic care needs, a revolving line of credit eliminates the friction of repeated applications and provides greater financial predictability.
Once approved, the patient has a financing tool they can use at their health system without reapplying for each new balance. This is particularly important for patients receiving repeat care such as oncology, infusion therapy, chronic disease management, or cardiac care.
For health systems, the revolving structure can support greater per-patient revenue capture over time while strengthening patient retention.
A provider-branded revolving line of credit ties the patient’s financing relationship directly to the health system rather than to a third-party card network.
Health systems using CURAEPay report a 22% reduction in overall patient bad debt and a 2x to 3x improvement in patient collections for balances between $1,000 and $10,000.
Revolving Credit vs. Other Patient Financing Options
A medical revolving line of credit differs fundamentally from both single-use medical loans and in-house payment plans.
A single-use medical loan is issued for one balance and typically requires another application for the next episode of care.
An in-house payment plan is not a credit facility. It does not transfer financial risk, accelerate cash, or provide the patient with a reusable financing tool.
CURAEPay offers qualifying patients a revolving line of credit of up to $10,000 that can be used for current and future healthcare balances without reapplying for each episode of care.
Why Institutional Capital Matters
The structure of a patient financing product determines its results. The capital behind it determines how long and under what conditions it can deliver those results.
Patient financing programs may remain active for years. The health system’s future revenue and the patient’s financial experience therefore depend on the financing program remaining stable, fully funded, and operationally consistent.
Institutional capital backed by a U.S.-based, publicly traded, federally regulated financial institution provides a stable capital base, established regulatory framework, and long-term operational continuity.
Credit lines offered through CURAEPay are issued by a federally regulated bank. Curae and its affiliates manage patient enrollment, eligibility determination, account servicing, and health system funding.
CURAEPay operates under the framework of U.S. federal banking regulation, including Regulation B under the Equal Credit Opportunity Act and Regulation Z under the Truth in Lending Act.
The Provider-Branded Loyalty Dimension
CURAEPay provides a provider-branded payment card that incorporates the participating health system’s name and brand identity.
This allows the patient financing experience to maintain a visible connection to the healthcare provider.
For health systems focused on patient retention and market share, the brand structure of a financing product should be evaluated alongside its financial and operational performance.
Key Takeaway
A medical revolving line of credit gives patients a reusable financing option for current and future healthcare needs while allowing health systems to accelerate cash, transfer financial risk, and strengthen the patient relationship.
But the structure of the credit product is only part of the equation.
The stability, regulatory framework, and source of capital behind the financing program can determine whether that patient financing solution remains reliable for years to come.
Read the Full Article
Learn how revolving patient credit differs from single-use medical loans and in-house payment plans, and why institutional capital should be part of every health system’s patient financing evaluation.
Questions?
Gary Johnson
Chief Growth Officer, CURAE®
gary.johnson@curae.com
678-643-9801
Curae® is a registered trademark of Curae Finance, LLC. CURAEPay is the patient payment financing solution within Curae’s Patient Financial Access Platform. Curae credit lines are issued by The Bank of Missouri, Perryville, MO.